Related Experiment Videos
Prostaglandin E2 and cyclic AMP in the coronary vasodilatation due to cardiac hyperactivity
Insights
Prostaglandin E2 (PGE2) affects cardiac adenosine 3
Area of Science:
- Cardiovascular Physiology
- Cardiac Metabolism
- Pharmacology
Background:
- Norepinephrine (NE) and calcium chloride (Ca2+) stimulate the heart, increasing coronary flow (CF) and cardiac adenosine 3',5'-cyclic phosphate (cAMP) levels.
- Prostaglandin E2 (PGE2) influences cardiac function and cAMP regulation.
- Diazoxide (Dx), a phosphodiesterase inhibitor, affects cAMP levels.
Purpose of the Study:
- To investigate the role of prostaglandin E2 (PGE2) in modulating cardiac adenosine 3',5'-cyclic phosphate (cAMP) levels and coronary flow (CF).
- To examine the interaction between PGE2, cardiostimulants (norepinephrine, calcium chloride), and phosphodiesterase inhibition on cardiac function.
Main Methods:
- Isolated perfused rat heart model.
- Administration of norepinephrine (NE), calcium chloride (Ca2+), prostaglandin E2 (PGE2), and diazoxide (Dx).
- Measurement of cardiac force of contraction, coronary flow (CF), and cardiac adenosine 3',5'-cyclic phosphate (cAMP) levels.
- Use of propranolol to block beta-adrenergic receptors.
Main Results:
- PGE2 infusion alone did not alter baseline cardiac contraction, CF, or cAMP.
- NE or Ca2+ administration led to diminished increases in CF and cAMP in the presence of PGE2.
- Diazoxide augmented the changes in CF and cAMP induced by NE or Ca2+.
- Propranolol blocked NE-induced effects but not Ca2+-induced effects.
Conclusions:
- PGE2 modulates cardiac cAMP levels, which are crucial for adaptive regulation of coronary flow (CF).
- Increased cardiac activity itself may contribute to changes in cAMP levels.
- The interplay between PGE2, cAMP, and cardiostimulants offers insights into cardiac regulation.
Abstract:
In the isolated perfused rat heart, the dose-related cardiostimulation produced by norepinephrine (NE) or calcium chloride (Ca2+) was followed by a corresponding increase in coronary flow (CF) and in the cardiac level of adenosine 3',5'-cyclic phosphate (cAMP). Prolonged prostaglandin E2 (pge2) infusion did not change the basic force of contraction, CF, or cAMP level but when NE or Ca2+ were administered, only the responses of the CF and the cAMP were diminished. A phosphodiesterase inhibitor, diazoxide (Dx), caused insignificant increase in the basal cAMP, without affecting the force of contraction or CF. With NE or Ca2+, during Dx both the changes in CF and cAMP were augmented compared to the nontreated hearts. The inhibitory effects of NE or Ca2+ remained unchanged. Propranolol abolished the NE but not the Ca2+ effects. It is suggested that PGE2 modulates the cardiac cAMP level and that the latter plays an important role in the adaptive regulation of the CF. It is also postulated that changes in cAMP levels may be brought about by the hyperactivity per se produced by a variety of cardiostimulating agents.